Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

Peter C. Taylor, Edward Keystone, Désirée van der Heijde, +12

New England Journal of Medicine

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

Josef S Smolen, Mark C. Genovese, Tsutomu Takeuchi, +9

The Journal of Rheumatology

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (<scp>UNCOVER</scp>‐J)

Hidehisa Saeki, Hidemi Nakagawa, Ko Nakajo, +5

The Journal of Dermatology

Isolation and Expression Profiling of Genes Upregulated in the Peripheral Blood Cells of Systemic Lupus Erythematosus Patients

Taeko Ishii, Hiroaki Onda, Akie Tanigawa, +13

DNA Research

ImmunologyPathologyImmunotherapySle PatientsGene Expression Profiling +16

Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis

Hidehisa Saeki, Hidemi Nakagawa, Taeko Ishii, +4

Journal of the European Academy of Dermatology and Venereology

Enhanced local production of osteopontin in rheumatoid joints.

Shiro Ohshima, Norihiko Yamaguchi, Katsuhiro Nishioka, +16

PubMed

RANKL-Induced Expression of Tetraspanin CD9 in Lipid Raft Membrane Microdomain Is Essential for Cell Fusion During Osteoclastogenesis

Masaru Ishii, Kaori Iwai, Masato Koike, +8

Journal of Bone and Mineral Research

Cell Cycle-Dependent Rho GTPase Activity Dynamically Regulates Cancer Cell Motility and Invasion In Vivo

Yoshinori Kagawa, Shinji Matsumoto, Yuji Kamioka, +22

PLoS ONE

Cell CycleCancer BiologyTumor BiologySignaling PathwayCell Regulation +18

Clinical usefulness of fractional exhaled nitric oxide for diagnosing prolonged cough

Suguru Sato, Junpei Saito, Yasuko Sato, +5

Respiratory Medicine

AsthmaPulmonary CareAllergyMedicinePulmonary Pharmacology +5

Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials

Masayoshi Harigai, Tsutomu Takeuchi, Josef S Smolen, +9

Modern Rheumatology